The subscription price for the warrants of series TO4 in PEPTONIC medical AB has been determined to SEK 0.028 and the exercise period starts April 17, 2024
The subscription price for the warrants of series TO4 in
If all the warrants of series TO4 are exercised, the Company will receive approximately
Summarized terms for the warrants of series TO4:
Exercise period:
Issue size: 196,370,600 warrants of series TO4, which entitles to subscription of 196,370,600 shares. If all warrants are exercised, the Company will receive approximately
Exercise price:
Last day for trading warrants of series TO4:
Share capital and dilution: If all warrants are exercised the share capital will increase with SEK
4,909,265.00, from approximately
Please be advised: The invested amount must be rounded up to two decimal places.
Please note that warrants that are not exercised on or before
How warrants are exercised:
Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Direct-registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
The application form including instructions for payment will be available at the Company’s website, www.peptonicmedical.se, and on
Advisers
For further information, please contact:
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About
The company continuously aims to broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company’s mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio. Central to the growth strategy is the geographic expansion of VagiVital and Vernivia through local partners.
Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in
https://news.cision.com/peptonic-medical-ab/r/the-subscription-price-for-the-warrants-of-series-to4-in-peptonic-medical-ab-has-been-determined-to-,c3962621
(c) 2024 Cision. All rights reserved., source